Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide

Neuro-Oncology

Volumn 18, Issue 11, 2016, Pages 1529-1537

  Wick, Wolfgang ^a,b,p   Roth, Patrick ^c   Hartmann, Christian ^c,d   Hau, Peter ^e   Nakamura, Makoto ^d   Stockhammer, Florian ^f,j   Sabel, Michael C ^g   Wick, Antje ^a,p   Koeppen, Susanne ^h   Ketter, Ralf ⁱ   Vajkoczy, Peter ^f   Eyupoglu, Ilker ^k   Kalff, Rolf ^l   Pietsch, Torsten ^f   Happold, Caroline ^b   Galldiks, Norbert ^m   Schmidt Graf, Friederike ^n,p   Bamberg, Michael ^p   Reifenberger, Guido ^o,p   Platten, Michael ^a,g,p   Von Deimling, Andreas ^a,b   Meisner, Christoph ^q   Wiestler, Benedikt ^a,b,q   Weller, Michael ^c,p   more..

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^d HANNOVER MEDICAL SCHOOL   (Germany)

^e UNIVERSITY OF REGENSBURG   (Germany)

^f CharitCrossed D Sign ^*

^g HEINRICH HEINE UNIVERSITY   (Germany)

^h UNIVERSITY HOSPITAL ESSEN   (Germany)

ⁱ SAARLAND UNIVERSITY   (Germany)

^j UNIVERSITY OF GÖTTINGEN   (Germany)

^k UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^l FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^m UNIVERSITY OF COLOGNE   (Germany)

ⁿ TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^o Partner Site   (Germany)

^p UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^q TECHNICAL UNIVERSITY OF MUNICH   (Germany)

more..

Author keywords

1p 19q; Anaplastic gliomas; CIMP; MGMT

Indexed keywords

LOMUSTINE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PROCARBAZINE; TEMOZOLOMIDE; VINCRISTINE; ALKYLATING AGENT; ANTINEOPLASTIC AGENT; DACARBAZINE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CHEMORADIOTHERAPY; CHROMOSOME 19Q; CHROMOSOME 1P; CHROMOSOME DELETION; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CPG ISLAND; DRUG EFFICACY; DRUG TREATMENT FAILURE; FEMALE; GLIOBLASTOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; RADIATION SAFETY; RANDOMIZED CONTROLLED TRIAL; TIME TO TREATMENT; ANALOGS AND DERIVATIVES; BRAIN NEOPLASMS; CLINICAL TRIAL; DISEASE FREE SURVIVAL; GLIOMA; MIDDLE AGED; PROCEDURES; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CHEMORADIOTHERAPY; DACARBAZINE; DISEASE-FREE SURVIVAL; FEMALE; GLIOMA; HUMANS; LOMUSTINE; MALE; MIDDLE AGED; PROCARBAZINE; TREATMENT OUTCOME; VINCRISTINE; YOUNG ADULT;

EID: 84994593666     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/now133     Document Type: Article

References (25)

1. van den Bent MJ, Brandes AA, Taphoorn MJ, et al Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951 J Clin Oncol 2013 31 3 344-350
2. van den Bent MJ, Brandes AA, Taphoorn M J, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol. 2013;31(3): 344-350. 2. Cairncross G, Wang M, Shaw E, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol. 2013;31(3):337-343.
3. Buckner JC, Pugh SL, Shaw EG, et al. Phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and vincristine (PCV) in low-grade glioma: RTOG 9802 with Alliance, ECOG, and SWOG. J Clin Oncol. 2014;32:5s (suppl; abstr 2000).
4. Hartmann C, Hentschel B, Wick W, et al. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status ac counts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol. 2010;120(6):707-718.
5. Wiestler B, Capper D, Sill M, et al. Integra ted DNA methylation and copy-number profiling identify three clinically and biologically relevant groups of anaplastic glioma. Acta Neuropathol. 2014; 128(4):561-571.
6. Weller M, Weber RG, Willscher E, et al. Molecular classification of diffuse cerebral WHO grade II/III gliomas using genomeand transcriptome-wide profiling improves stratification of prognostically distinct patient groups . Acta Neuropathol. 2015; 129(5):679-693.
7. Suzuki H, Aoki K, Chiba K, et al. Mutational landscape and clonal architecture in grade II and III gliomas. Nat Genet. 2015;47(5): 458-468.
8. Cancer Genome Atlas Research Network. Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med. 2015;372(26):2481-2498.
9. Reuss DE, Mamatjan Y, Schrimpf D, et al. IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHO. Acta Neuropathol. 2015 a;129(6):867-873.
10. Reuss DE, Kratz A, Sahm F, et al. Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities. Acta Neuropathol. 2015b ;130(3):407-417.
11. Wick W, Meisner C, Hentschel B, et al. Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation. Neurology. 2013;81(17):1515-1522.
12. Wiestler B, Capper D, Holland-Letz T, et al. ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis. Acta Neuropathol. 2013;126(3) :443-451.
13. Sahm F, Reuss D, Koelsche C, et al. Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma. Acta Neuropathol. 2014;128(4): 551-559.
14. Reuss DE, Sahm F, Schrimpf D, et al. ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an " integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma. Acta Neuropathol. 2015;129(1):133-146.
15. Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of t he central nervous system. Acta Neuropathol. 2007;114(5):97-109.
16. Louis DN, Perry A, Burger P, et al. International Society Of Neuropathology-Haarlem consensus guidelines for nervous system t umor classification and grading. Brain Pathol. 2014; 24(6):429-435.
17. Wick W, Hartmann C, Engel C, et al. for the Neurooncology Working Group (NOA) of the German Cancer Society. NOA-04 ran domized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide. J Clin Oncol. 2009; 27(35):5874-5880.
18. Mogensen UB, Ishwaran H, Gerds TA. Evaluating random forests for survival analysis using prediction error curves. J Stat Softw. 2012;50(11):1-23.
19. Wiestler B, Capper D, Hovestadt V, et al. Assessing CpG island methylator phenotype, 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide data in the biomarker cohort of the NOA-04 trial. Neuro Oncol. 2014;16(12):1630-1638.
20. Lassman AB, Iwamoto FM, Cloughesy TF, et al. International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors. Neuro Oncol. 2011;13(6):649-659.
21. Chang SM, Zhang P, Cairncross JG, et al Results of NRG oncology/ RTOG 9813: A phase III randomized study of radiation therapy (RT) and temozolomide (TMZ) versus RT and nitrosourea (NU) therapy for anaplastic astrocytoma (AA). J Clin Oncol 2015 33. (suppl; abstr 2002)
22. Weller M, WickW. Neuro-oncology in 2013: Improving outcome in newly diagnosed malignant glioma. Nat Rev Neurol. 2014;10(2): 68-70.
23. Weller M,WickW, Aldape K, et al. Glioma. Nat Rev Dis Primers. 2015; 1:15017.
24. Schumacher T, Bunse L, Pusch S, et al. A vaccine targeting mutant IDH1 induces antitum or immunity. Nature. 2014;512(7514): 324-327.
25. Rohle D, Popovici-Muller J, Palaskas N, et al. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science. 2013;340(6132):626-630.